CHICAGO – Advanced melanoma therapy – a field notorious for offering patients few drugs and little chance of survival – may be on the brink of an extraordinary transformation.
"There’s truly a revolution going in the immunotherapy of melanoma," explained Dr. Steven O’Day of the Beverly Hills (Calif.) Cancer Center.
In a video interview at the annual meeting of the American Society for Clinical Oncology, Dr. O’Day reviews the rapid developments in melanoma treatment options and the shift from a "nuclear bomb" approach to a more-targeted "cruise missile" mindset. He also highlights the parallels between the exceptional advances made in childhood leukemia treatment and new melanoma treatments such as ipilimumab and PD-1 inhibitors, and he discusses the new drugs’ ability to overcome a phenomenon that often defeats chemotherapy: cancer cell resistance.
function runABTest(_videoIDs) { var rand = Math.floor(Math.random() * _videoIDs.length); return _videoIDs[rand]; } function delvePlayerCallback(playerId, eventName, data) { if (eventName == 'onPlayerLoad') DelvePlayer.doLoadMedia(runABTest (['32effa5913274f2c95e538a17315f137','7504d03ff06d490f8db8b6f4cb484228'])); } LimelightPlayerUtil.initEmbed('limelight_player_156792');